Omega-3 prevents behavior response and brain oxidative damage in the ketamine model of schizophrenia
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Supplementation with omega-3 has been identified as an adjunctive alternative for the treatment of psychiatric disorders, in order to minimize symptoms. Considering the lack of understanding concerning the pathophysiology of schizophrenia, the present study hypothesized that omega 3 prevents the onset of symptoms similar to schizophrenia in young Wistar rats submitted to ketamine treatment. Moreover, the role of oxidative stress in this model was assessed. Omega-3 (0.8g/kg) or vehicle was given by orogastric gavage once daily. Both treatments were performed during 21days, starting at the 30th day of life in young rats. After 14days of treatment with omega-3 or vehicle, a concomitant treatment with saline or ketamine (25mg/kg ip daily) was started and maintained until the last day of the experiment. We evaluated the pre-pulse inhibition of the startle reflex, activity of antioxidant systems and damage to proteins and lipids. Our results demonstrate that supplementation of omega-3 prevented: decreased inhibition of startle reflex, damage to lipids in the hippocampus and striatum and damage to proteins in the prefrontal cortex. Furthermore, these changes are associated with decreased GPx in brain tissues evaluated. Together, our results suggest the prophylactic role of omega-3 against the outcome of symptoms associated with schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Brain foods: The effects of nutrients on brain function.
Gómez-Pinilla, F. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2421 · Cited by 1,372
Oxidative stress in psychiatric disorders: evidence base and therapeutic implications
Ng, F., Berk, M., Dean, O., & Bush, A. I. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008401 · Cited by 1,069
Amminger, G. P., Schäfer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., Mackinnon, A., McGorry, P. D., & Berger, G. E. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.192 · Cited by 896
Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo
Do, K. Q., Trabesinger, A. H., Kirsten‐Krüger, M., Lauer, C. J., Dydak, U., Hell, D., Holsboer, F., Boesiger, P., & Cuénod, M. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00229.x · Cited by 540
Essential fatty acids and the brain: possible health implications
Youdim, K. A., Martin, A., & Joseph, J. A. (2000) · International Journal of Developmental Neuroscience · doi:10.1016/s0736-5748(00)00013-7 · Cited by 517
Peet, M., Brind, J., Ramchand, C. N., Shah, S., & Vankar, G. K. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00083-9 · Cited by 329
Antioxidants, Redox Signaling, and Pathophysiology in Schizophrenia: An Integrative View
Yao, J. K., & Keshavan, M. S. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3603 · Cited by 285
das Neves Duarte, J. M., Kulak, A., Gholam-Razaee, M. M., Cuenod, M., Gruetter, R., & Do, K. Q. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.07.035 · Cited by 124
Sivrioglu, E. Y., Kirli, S., Sipahioglu, D., Gursoy, B., & Sarandöl, E. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.07.004 · Cited by 102
Cited by
Altering the course of schizophrenia: progress and perspectives
Millan, M. J., Andrieux, A., Bartzokis, G., Cadenhead, K., Dazzan, P., Fusar-Poli, P., Gallinat, J., Giedd, J., Grayson, D. R., Heinrichs, M., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.28 · Cited by 516
Smaga, I., Niedzielska, E., Gawlik, M., Moniczewski, A., Krzek, J., Przegaliński, E., Pera, J., & Filip, M. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2014.12.015 · Cited by 252
Lipids in Psychiatric Disorders and Preventive Medicine
Schneider, M., Levant, B., Reichel, M., Gulbins, E., Kornhuber, J., & Müller, C. P. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.06.002 · Cited by 175
Do, K. Q., Cuenod, M., & Hensch, T. K. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv065 · Cited by 158
Healy-Stoffel, M., & Levant, B. (2018) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527317666180412153612 · Cited by 133
Metadata
- Authors
- Zugno, A. I., Chipindo, H. L., Volpato, A. M., Budni, J., Steckert, A. V., de Oliveira, M. B., Heylmann, A. S., Silveira, F. D. R., Mastella, G. A., Maravai, S. G., Wessler, P. G., Binatti, A. R., Panizzutti, B., Schuck, P. F., Quevedo, J., & Gama, C. S.
- Venue
- Neuroscience
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 259
- Pages
- 223-231
- ISSN
- 0306-4522 (ISSN-L)
- OpenAlex
- W1999332404
- Cited by
- 74
- References
- 11
- FWCI
- 7.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Omega-3 prevents behavior response and brain oxidative damage in the ketamine model of schizophrenia. https://app.cochat.ai/papers/10.1016/j.neuroscience.2013.11.049
- The paper
- Zugno, A. I., Chipindo, H. L., Volpato, A. M., Budni, J., Steckert, A. V., de Oliveira, M. B., Heylmann, A. S., Silveira, F. D. R., Mastella, G. A., Maravai, S. G., Wessler, P. G., Binatti, A. R., Panizzutti, B., Schuck, P. F., Quevedo, J., & Gama, C. S. (2014). Omega-3 prevents behavior response and brain oxidative damage in the ketamine model of schizophrenia. Neuroscience. https://doi.org/10.1016/j.neuroscience.2013.11.049
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.